81/100BVertex Pharmaceuticals stock forecast 2026–2030What is an analyst price target? A price target is the price an analyst expects a stock to reach in 12 months. Arincen shows the average, high and low targets and the upside to the average.
Analysts' average 12-month price target for Vertex Pharmaceuticals is 580.20, 6.1% above the current price of 547.03. Their targets range from 350.00 to 665.00.
Of the 24 firms that rated Vertex Pharmaceuticals in the past 12 months, 21 rate it buy or strong buy, 2 hold and 1 sell or strong sell (each firm at its latest rating): a Strong buy consensus.
Analysts' 1-year price targets range from 350.00 to 665.00, with an average of 580.20.
| Buy | 21 | |
| Hold | 2 | |
| Sell | 1 |
12-month price target
| Highest target | 665.00 |
| Average target | 580.20 |
| Lowest target | 350.00 |
| Current price | 547.03 |
Vertex Pharmaceuticals price target historyWhat is an analyst price target? A price target is the price an analyst expects a stock to reach in 12 months. Arincen shows the average, high and low targets and the upside to the average.
Have analysts recently raised or lowered their Vertex Pharmaceuticals price target and rating?
How analysts rate Vertex Pharmaceuticals, month by monthWhat is the analyst rating? The analyst rating sums up what the analysts covering a stock recommend, from strong buy to strong sell, by the share of them rating it a buy.
21 of 24 firms rate it buy now, against 14 of 20 in December 2025.
Each month: every firm at its latest rating from the 12 months before. Strong buys count as buys, strong sells as sells.
Vertex Pharmaceuticals analyst upgrades, downgrades and price targets
The latest rating change came on 18 March 2026, when Maxim Group upgraded Vertex Pharmaceuticals from Hold to Buy. The most recent new target came from Cantor Fitzgerald on 3 November 2026: 619.00.
| Date | Firm | Rating | Price target | Change | Price then |
|---|---|---|---|---|---|
| 3 Nov 2026 | Cantor Fitzgerald Carter Gould | Reiterated · Overweight | 595.00 → 619.00 | +4.0% | 535.42 |
| 3 Nov 2026 | Wells Fargo Mohit Bansal | Reiterated · Overweight | 650.00 | — | 553.15 |
| 8 Oct 2026 | RBC Capital | Reiterated · Outperform | 570.00 → 576.00 | +1.1% | 502.62 |
| 28 Sept 2026 | UBS | Reiterated · Buy | 585.00 → 615.00 | +5.1% | 528.04 |
| 23 Sept 2026 | Jefferies Akash Tewari | — | 580.00 → 640.00 | +10.3% | 514.99 |
| 22 Sept 2026 | H.C. Wainwright Andrew Fein | — | 591.00 → 641.00 | +8.5% | 519.67 |
| 1 Sept 2026 | Morgan Stanley Terence Flynn | — | 616.00 → 665.00 | +8.0% | 547.65 |
| 1 Sept 2026 | Goldman Sachs | — | 653.00 | — | 544.52 |
| 11 Aug 2026 | Bernstein Jeffrey Walch | — | 572.00 → 608.00 | +6.3% | 530.29 |
| 10 Aug 2026 | Wolfe Research Andy Chen | — | 562.00 | — | 522.78 |
| 5 Aug 2026 | Truist Financial | Reiterated · Buy | 560.00 → 565.00 | +0.9% | 488.56 |
| 5 Aug 2026 | Barclays | Reiterated · Overweight | 615.00 → 617.00 | +0.3% | 478.71 |
| 4 Aug 2026 | Cantor Fitzgerald | Reiterated · Overweight | 590.00 → 595.00 | +0.8% | 470.72 |
| 4 Aug 2026 | Canaccord Genuity | Reiterated · Hold | 436.00 → 442.00 | +1.4% | 470.72 |
| 4 Aug 2026 | Stifel Nicolaus | — | 466.00 → 500.00 | +7.3% | 470.72 |
| 13 Jul 2026 | UBS | Reiterated · Buy | 545.00 → 585.00 | +7.3% | 481.70 |
| 13 Jul 2026 | Truist Financial | Reiterated · Buy | 542.00 → 560.00 | +3.3% | 479.02 |
| 7 Jul 2026 | RBC Capital | Reiterated · Outperform | 543.00 → 570.00 | +5.0% | 529.59 |
| 7 Jul 2026 | Robert W. Baird | — | 350.00 | — | 529.59 |
| 27 May 2026 | Truist Financial Danielle Brill | — | 525.00 → 542.00 | +3.2% | 435.93 |
| 6 May 2026 | Barclays | Reiterated · Overweight | 607.00 → 615.00 | +1.3% | 424.36 |
| 5 May 2026 | Morgan Stanley | Reiterated · Overweight | 612.00 → 616.00 | +0.7% | 417.72 |
| 5 May 2026 | RBC Capital Brian Abrahams | Reiterated · Outperform | 541.00 → 543.00 | +0.4% | 429.85 |
| 5 May 2026 | Bernstein | Reiterated · Outperform | 577.00 → 572.00 | -0.9% | 429.85 |
| 5 May 2026 | Canaccord Genuity | Reiterated · Hold | 437.00 → 436.00 | -0.2% | 429.85 |
| 30 Apr 2026 | Canaccord Genuity | Reiterated · Hold | 441.00 → 437.00 | -0.9% | 423.24 |
| 10 Apr 2026 | Morgan Stanley | Reiterated · Overweight | 570.00 → 612.00 | +7.4% | 436.89 |
| 18 Mar 2026 | Maxim Group | Upgraded · Hold → Buy | — | — | — |
| 10 Mar 2026 | Truist Financial Joon Lee | — | 490.00 → 525.00 | +7.1% | 499.14 |
| 10 Mar 2026 | Jefferies Akash Tewari | — | 580.00 | — | 496.50 |
| 2 Mar 2026 | BMO Capital Evan David Seigerman | — | 530.00 → 600.00 | +13.2% | 487.57 |
| 17 Feb 2026 | Canaccord Genuity | Reiterated · Hold | 441.00 | — | 491.47 |
| 17 Feb 2026 | Barclays Eliana Merle | Reiterated · Overweight | 606.00 → 607.00 | +0.2% | 491.47 |
| 17 Feb 2026 | H.C. Wainwright Andrew Fein | — | 518.00 → 591.00 | +14.1% | 491.47 |
| 13 Feb 2026 | Morgan Stanley Terence Flynn | — | 564.00 → 570.00 | +1.1% | 497.42 |
| 13 Feb 2026 | Scotiabank Louise Chen | Reiterated · Sector Perform | 442.00 → 558.00 | +26.2% | 493.98 |
| 13 Feb 2026 | RBC Capital | Reiterated · Outperform | 546.00 → 541.00 | -0.9% | 496.02 |
| 13 Feb 2026 | Bernstein | — | 577.00 | — | 497.21 |
| 13 Feb 2026 | Cantor Fitzgerald | — | 485.00 → 590.00 | +21.6% | 495.11 |
| 13 Feb 2026 | Stifel Nicolaus Paul Matteis | Reiterated · Hold | 445.00 → 466.00 | +4.7% | 465.02 |
| 13 Feb 2026 | H.C. Wainwright Andrew Fein | — | 478.00 → 518.00 | +8.4% | 465.02 |
| 13 Feb 2026 | Oppenheimer | Upgraded · Perform → Outperform | — | — | — |
| 28 Jan 2026 | Barclays | Upgraded · Equal Weight → Overweight | — | — | — |
| 27 Jan 2026 | Barclays | — | 414.00 → 606.00 | +46.4% | 474.17 |
| 26 Jan 2026 | UBS | Reiterated · Buy | 535.00 → 545.00 | +1.9% | 474.09 |
| 23 Jan 2026 | Evercore ISI Cory Kasimov | Reiterated · Outperform | 530.00 | — | 469.11 |
| 22 Jan 2026 | RBC Capital Brian Abrahams | Upgraded · Sector Perform → Outperform | 415.00 → 546.00 | +31.6% | 461.14 |
| 12 Jan 2026 | Bernstein | Upgraded · Market Perform → Outperform | — | — | — |
| 6 Jan 2026 | UBS Michael Yee | — | 553.00 → 535.00 | -3.3% | 468.38 |
| 6 Jan 2026 | Wolfe Research | Upgraded · Peer Perform → Outperform | — | — | — |
Vertex Pharmaceuticals EPS and revenue estimatesWhat are estimate revisions? Estimate revisions are the changes analysts make to their EPS and revenue forecasts for the years ahead. They show whether expectations are rising or falling.
Revenue
EPS
Does Vertex Pharmaceuticals beat earnings estimates?What is an earnings surprise? An earnings surprise is how far a company's reported EPS or revenue came above or below the analysts' average estimate, in percent.
On average, analysts' EPS estimate was 5.0% off the result, either way, and their revenue estimate 1.9%, over the last 12 quarters.
- EPS beats
- 77 / 134
- Revenue beats
- 79 / 120
- Average EPS surprise, last 12What is an earnings surprise? An earnings surprise is how far a company's reported EPS or revenue came above or below the analysts' average estimate, in percent.
- +1.9%
- Since
- February 1993
| Quarter | Report date | EPS estimate | Reported EPS | Surprise | Revenue estimate | Reported revenue | Surprise |
|---|---|---|---|---|---|---|---|
| Q3 FY2026 | 2 Nov 2026 | 4.82 | 4.76 | -1.2% | 3.42B | 3.44B | +0.6% |
| Q2 FY2026 | 3 Aug 2026 | 4.74 | 4.73 | -0.2% | 3.23B | 3.33B | +3.2% |
| Q1 FY2026 | 4 May 2026 | 4.24 | 4.47 | +5.4% | 2.99B | 2.99B | -0.2% |
| Q4 FY2025 | 12 Feb 2026 | 5.11 | 5.03 | -1.6% | 3.18B | 3.19B | +0.2% |
| Q3 FY2025 | 3 Nov 2025 | 4.57 | 4.80 | +5.0% | 3.06B | 3.08B | +0.6% |
| Q2 FY2025 | 4 Aug 2025 | 4.29 | 4.52 | +5.4% | 2.91B | 2.96B | +2.0% |
| Q1 FY2025 | 5 May 2025 | 4.25 | 4.06 | -4.5% | 2.86B | 2.77B | -3.2% |
| Q4 FY2024 | 10 Feb 2025 | 4.02 | 3.98 | -1.0% | 2.78B | 2.91B | +4.6% |
| Q3 FY2024 | 4 Nov 2024 | 4.14 | 4.38 | +5.8% | 2.69B | 2.77B | +3.2% |
| Q2 FY2024 | 1 Aug 2024 | -11.63 | -12.83 | -10.3% | 2.66B | 2.63B | -1.1% |
| Q1 FY2024 | 6 May 2024 | 4.06 | 4.76 | +17.2% | 2.58B | 2.69B | +4.1% |
| Q4 FY2023 | 5 Feb 2024 | 4.10 | 4.20 | +2.4% | 2.51B | 2.52B | +0.2% |
Vertex Pharmaceuticals stock price 2026–2030: scenariosHow are the stock price scenarios calculated? Bear, base and bull prices for the years ahead: the analysts' EPS estimates times the lowest, average and highest P/E of the stock today and at its last five year ends, or of its peers.
If Vertex Pharmaceuticals's earnings keep growing at the 9.4% a year analysts expect to FY2028, it would earn about 28.83 a share in FY2030. At the P/E it has traded at over the last five years (22.3 to 34.9) that is 641.81 to 1,006.93 a share, or 805.04 at its average P/E of 27.9. This is arithmetic on the analysts' estimates, not a prediction.
| Fiscal year | EPS | Bear | Base | Bull |
|---|---|---|---|---|
| FY2026 | 18.23 | 405.95 | 509.20 | 636.89 |
| FY2027 | 20.16 | 448.94 | 563.13 | 704.34 |
| FY2028 | 24.09 | 536.43 | 672.87 | 841.60 |
| FY2029 (extrapolated) | 26.35 | 586.76 | 735.99 | 920.56 |
| FY2030 (extrapolated) | 28.83 | 641.81 | 805.04 | 1,006.93 |
Each year's EPS is the analysts' consensus to FY2028; the years after grow 9.4% a year (the analysts' growth, at most 15%). Bear, base and bull apply the lowest, average and highest P/E of today and the last five fiscal year ends, leaving out any above 60, the mark of a year of collapsed earnings (22.3, 27.9, 34.9).
Most undervalued US stocksHow does Arincen work out a stock's fair value? Fair value is our estimate of a share's price at the P/E the company usually trades at, with a low to high range around it.
| Stock | Price | Fair value | Upside |
|---|---|---|---|
| 99.090 | 194.93146Price 99.09244 | +96.7% | |
| 42.225 | 82.9546Price 42.23165 | +96.4% | |
| 186.680 | 360.82271Price 186.68451 | +93.3% | |
| 213.670 | 405.57304Price 213.67507 | +89.8% | |
| 161.160 | 305.51157Price 161.16396 | +89.6% | |
| 160.650 | 300.09225Price 160.65375 | +86.8% | |
| 165.860 | 308.95212Price 165.86442 | +86.3% |
Furthest below the fair value on each stock's page, updated every day.